Literature DB >> 1580296

Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic.

J H Samet1, H Libman, K A Steger, R K Dhawan, J Chen, A H Shevitz, R Dewees-Dunk, S Levenson, D Kufe, D E Craven.   

Abstract

PURPOSE: To determine the extent of and clinical variables associated with zidovudine compliance. PATIENTS AND METHODS: A survey of 83 patients infected with human immunodeficiency virus (HIV) followed in a municipal hospital clinic was performed. Compliance histories were validated by serum and urine zidovudine levels. Patient characteristics included 46% white, 63% with a history of intravenous drug use, and 59% reporting a diagnosis of acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). The main outcome measure was greater than 80% compliance with prescribed doses of zidovudine over the previous week.
RESULTS: Sixty-seven percent of the study patients reported greater than 80% compliance with prescribed doses of zidovudine over the previous week. The most common explanations given for missing a dose were "forgot to take zidovudine" and "did not have the medication with me." Five variables were independently associated with greater than 80% compliance as determined by stepwise multiple logistic regression: patient belief that zidovudine prolongs life (odds ratio [OR] 9.3, [95% confidence interval (CI) 2.4, 36.7]), a diagnosis of AIDS or ARC (OR 5.5, [CI 1.5, 20.4]), use of a medication timer (OR 4.4, [CI 1.0, 19.1]), no history of intravenous drug use (OR 3.7, [CI 1.0, 14.2]), and taking one to three other medications with zidovudine.
CONCLUSIONS: High compliance with zidovudine was achieved by HIV-infected patients in a municipal hospital clinic, many of whom had a history of intravenous drug use. Compliance with zidovudine may be enhanced by a patient's belief that it prolongs life and the use of a medication timer for proper dosing.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1580296     DOI: 10.1016/0002-9343(92)90746-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  34 in total

1.  When should we delay highly active antiretroviral therapy?

Authors:  D R Bangsberg; A Moss
Journal:  J Gen Intern Med       Date:  1999-07       Impact factor: 5.128

2.  Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention.

Authors:  M O Rigsby; M I Rosen; J E Beauvais; J A Cramer; P M Rainey; S S O'Malley; K D Dieckhaus; B J Rounsaville
Journal:  J Gen Intern Med       Date:  2000-12       Impact factor: 5.128

3.  Behavior-changing methods for improving adherence to medication.

Authors:  C Willey
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

4.  Appreciating Reasons for Nonadherence in Women.

Authors:  Jennifer G Okonsky; Allison Webel; Carol Dawson Rose; Mallory Johnson; Alice Asher; Yvette Cuca; Alphoncina Kaihura; Jan E Hanson; Carmen J Portillo
Journal:  Health Care Women Int       Date:  2014-05-15

5.  Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: the impact of social network factors, side effects, and perceived treatment efficacy.

Authors:  Penelope A Demas; Donald M Thea; Jeremy Weedon; Janis McWayne; Mahrukh Bamji; Genevieve Lambert; Ellie E Schoenbaum
Journal:  Women Health       Date:  2005

Review 6.  Prevention and treatment of hepatitis C in injection drug users.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

7.  Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort.

Authors:  V E Stone; M Y Mauch; K Steger; S F Janas; D E Craven
Journal:  J Gen Intern Med       Date:  1997-03       Impact factor: 5.128

8.  Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.

Authors:  S J Ackerman; E M Sullivan; K M Beusterien; H M Natter; D F Gelinas; D L Patrick
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

9.  Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users.

Authors:  Frederick L Altice; Sandra Springer; Marta Buitrago; David P Hunt; Gerald H Friedland
Journal:  J Urban Health       Date:  2003-09       Impact factor: 3.671

10.  Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia.

Authors:  Sibhatu Biadgilign; Amare Deribew; Alemayehu Amberbir; Kebede Deribe
Journal:  BMC Pediatr       Date:  2008-12-06       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.